Viewing Study NCT06625320


Ignite Creation Date: 2025-12-25 @ 4:09 AM
Ignite Modification Date: 2026-01-04 @ 2:32 AM
Study NCT ID: NCT06625320
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-12
First Post: 2024-09-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Revolution Medicines, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module